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H and 13 C NMR spectra were obtained using a Bruker 500 or 600 MHz instrument unless otherwise noted. Chemical shifts were reported in parts per million (ppm, δ) referenced to the residual 1H resonance of the solvent (CDCl 3 , 7.26 ppm) or (CD 3 OD, 3.31 ppm). 13 C spectra were referenced to the residual 13 C resonance of the solvent (CDCl 3 , 77.0 ppm) or (CD 3 OD, 49.0 ppm). The LC/MS analysis was performed using an Agilent G-1956D single quadrupole mass spectrometer equipped with an 1100 series LC system from Agilent Technologies. HPLC separations were performed on a Vydac 218TP C18 reversed phase preparative (10−15 μm) HPLC column using a gradient of acetonitrile and water. Protein concentration was determined by BCA assay (Pierce BCA Protein Assay Kit) with analysis on a plate reader (Molecular Devices SpectraMax 250) at 562 nm36. High resolution mass spectra were obtained in the Scripps Center for Mass Spectrometry. Electrospray Ionization (ESI) mass were obtained on a ThermoFinnigan LTQ Ion Trap, and characterization of protein conjugates was carried out using comparative MALDI-MS, using sinapinic acid as the matrix on an Applied Biosystems VoyagerDE STR MS. Enzyme Expression. Expression was carried out as previously reported.
1 Briefly, the enzymes Galactose-4-epimerase (GalE) and α1,3-Galactosyltransferase (α1,3GalT) were overexpressed in the E. coli strain BL21(DE3) (Invitrogen) and purified using TALON® metal affinity resin (Clontech). Cell pellets were lysed with 5 mL of 0.2 g/L lysozyme (Sigma) in 20 mM PBS (pH 7.0) containing 1% Triton X-100, disrupted by gentle pipetting, incubated at 37°C on rotator for 20 min, treated with DNase I (New England Biolab), and incubated for 20 min at 37°C. Cell lysate was centrifuged at 16,000 rcf at 4°C for 20 min and supernatant added to 2 mL of TALON resin (Clonetech) pre-equilibrated with 20 mM PBS (pH 7.0) containing 0.3 M NaCl. The column was washed with 10 mL of 20 mM Sodium phosphate buffer (pH 7.0) containing 0.3 M NaCl and the protein was eluted using a step gradient with increasing concentrations of imidazole (20, 50, 100, and 200 mM) in 20 mM Sodium phosphate buffer (pH 7.0) containing 0.3 M NaCl. Protein purity in each 5mL fraction was visualized by SDS-PAGE. Fractions containing pure enzyme were pooled and concentrated to ~0.3-0.5 mL using an Amicon 4 centrifugal filter (MWCO 10-kDa) followed by dialysis against PBS. The final enzyme solution was added to equal volume of glycerol to make a 50% glycerol solution for storage at -20°C. Protein concentration was determined by BCA (Pierce). Overall protein yield from a 50 mL culture was ~1.5 mg for GalE and ~1.4 mg for α1,3GalT.
Immunoconjugation protocol. Dialyzed OVA, TT or BSA in 0.5M Borate buffer (pH 9.0) was added to 1 to give a final concentration of 1.25 mg/mL in 0.5 M Borate buffer (pH 9.0) and the solutions mixed at rt for 24 h. Hapten density for each conjugate was determined by MALDI-TOF mass analysis and compared to the MW of unmodified protein, per the formula: copy number = (MW αGal BSA -MW carrier) / (MW αGal -MW EtOH). The resulting protein conjugates were dialyzed into PBS (pH 7.4) at 4 °C. Compound 5 (5 mg) was dissolved in DMF:H 2 O (9:1). To this was added 0.06 mmol sulfo-NHS and 0.06 mmol EDC. Mixture stirred at rt for ~3.5 h. This solution was concentrated to one-third of volume under reduced pressure, and added to 1 equivilent of carrier or 1-carrier in PBS (pH 7.4). This mixture was stirred at 4 ºC overnight. The resulting solution was dialyzed into PBS (pH 7.0).
Animal Care and Use. All studies were performed in compliance with the Scripps Institutional Animal Care and Use Committee (La Jolla, CA), and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice with disrupted α1,3galactosyltransferase genes 2 (6-10 week old) were group-housed in an AAALAC-accredited vivarium containing temperature-and humidity-controlled rooms, with mice kept on a reverse light cycle (lights on: 9PM-9AM). All experiments were performed during the dark phase, generally between 1PM-4PM. General health was monitored by both the scientists and veterinary staff at The Scripps Research Institute. Mice were vaccinated against 1 as previously described. 1 For immunization with 6 or 7, 50 µg conjugate in ~50 µL sterile PBS (pH 7.4) was combined with 50 µL of Alhydrogel® (10 mg/mL, Invivogen). The resulting suspension was mixed and subsequently administered to mice intraperitoneally. Each mouse was bled via retro-orbital sinus on indicated days. Blood samples were then centrifuged at 10,000 rpm for 10 min to collect sera for further analysis.
S3
ELISA. Microtiter plates (Costar 3690) were incubated with coating antigen-BSA in PBS (4 μg/mL, 25 μL) for 18 h at 37 °C. 5% nonfat milk in PBS was added to block nonspecific binding for 30 mins at 37 ºC, then removed. Mouse sera was dilute in 2% BSA (1:100 for 1, 1:50 for 5) then serially diluted across the plate before incubation in a moist chamber (24 h, 4 °C). The plate was washed with dH 2 O before incubation with HRP-conjugated secondary (goat anti-mouse IgG (Abcam) or goat anti-mouse IgM (SouthernBiotech)) in a moist chamber for 2 h at 25 °C. The plates were further washed with dH 2 O before being developed with using TMB (Thermo Pierce) and the absorbance at 450 nm measured on a microplate reader (SpectraMax M2e Molecular Devices). Titers were calculated as the dilution corresponding to 50% of the maximum absorbance from a plot of the absorbance versus log(dilution) using Prism 6 (GraphPad). Subtyping end-point ELISA was carried out using an SBA Clonotyping System-HRP (SouthernBiotech, Birmingham, AL) according to manufacturers instructions using 1-BSA coated microtiter plates. Subtyping of 10 normal human serum samples was carried out using the same procedure, using mouse anti-huIgG1 (ab99774, Abcam, Cambridge, MA), mouse anti-huIgG2 (ab99779, Abcam), mouse anti-huIgG3 (9210-05, SouthernBiotech), and mouse anti-huIgG4 (ab99826, Abcam).
Surface Plasmon Resonance. The Ki for mouse serum binding to 1 was determined by a competitive binding assay via surface plasmon resonance using a Biacore 3000 instrument (GE Healthcare) equipped with a research-grade CM5 sensor chip. The ligand, 1-BSA conjugate, was immobilized using NHS, EDC coupling reaction. The surface of all flow cells were activated for 7 min with a 1:1 mixture of 0.1 M NHS and 0.1 M EDC at a flow rate of 5 μL/min. The ligand resuspended in 10 mM sodium acetate (pH 4.0) was immobilized at a density of 2,000 RU on flow cell 2; whereas flow cell 1 was immobilized with BSA at the same density to serve as a reference surface. All the surfaces were blocked with a 7 min injection of 1.0 M ethanolamine-HCl (pH 8.5). Mouse serum was diluted in running buffer (HBS-EP+ buffer) and titrated on both coated flow cells, so as to give a response of ~ 100 RU at the end of the injection with 5 min of injection and 2.5 min dissociation at a flow rate of 30 μL/min. Mouse serum at optimized binding concentration was incubated with 1 for 1 h at room temperature prior to injection. To collect binding data, the compound mixture was injected over the two flow cells at a flow rate of 30 μL/min at 25 °C for 5 min and was dissociated in buffer for 2.5 min before regeneration. The chip surface was regenerated by injection of 10 mM Gly-HCl (pH 2.2) for 30 seconds before the next injection. The response at the end of dissociation phase for each cycle of binding analysis was used to calculate the IC 50 value for each compound by GraphPad Prism 6 software.
Blood-Brain LC-MS. Mice (n > 5/group) were administered 20 mg/kg cocaine in a 10 mL/kg volume of physiological sterile saline via intraperitoneal injection. After 15 mins, mice were fully anesthetized using isoflurane, rapidly decapitated, and trunk blood was collected. Whole blood samples were centrifuged at ~10000 rcf for 10 min, and the serum collected. To a 300 µL aliquot of serum sample, 120 µL of 0.6M aq. NaF was added. To a 100 µL aliquot of this solution was added 100 µL of 326 nM cocaine-D 3 in acetonitrile and vortex mixed for 30 s. After equilibration, solidphase extraction was conducted by using an Oasis ® HLB µElution plate (Waters Corp, Milford, MA). The brain tissue was removed and immediately flash-frozen in a -78 ºC bath. To each frozen brain was added 1 mL of 0.6M aq. NaF, homogenized using a Bullet Blender ® (Next Advance, NY), and then centrifuged at ~1000 rpm for 10 min. To a 150 µL aliquot of the supernatant was added 150 µL of 326 nM cocaine-D 3 in acetonitrile and mixture vortexed for 30 s. After the equilibration, solid-phase extraction was conducted by using Oasis ® HLB µElution plate (Waters Corp, Milford, MA).
Mass spectrometry analysis was conducted on an Agilent 6100 Quadruple LC-MS system equipped with an Agilent ZORBAX SB-C8 column. Samples were run using H 2 O+0.1% formic acid and MeCN+0.1% formic acid as the mobile phase. The percentage of H 2 O+0.1% formic acid was linearly increased from 10-95% and the percentage of MeCN+0.1% formic acid was linearly decreased from 90-5% over a 7 minute run (500 µL/mL). Cocaine concentration was quantified via extraction and integration of the 304.35 [MW+H + ] mass peak using MassHunter (Agilent).
Integration was normalized to the internal standard, cocaine-D 3 . The normalized integration was compared to a 7point standard curve for cocaine, made using blank mouse serum that had been spiked with known concentrations (0 to 1 µM) of cocaine.
Open Field Hyperlocomotion. Animals were allowed to acclimate for one hour in a clean plastic cage (267 × 483 × 203 mm) with a clear ventilated acrylic top. Mice were then removed, injected IP with cocaine, and immediately returned to this cage to be recorded and tracked by an overhead camera for 90 min. Tests were conducted with a minimum 24 h washout period to clear cocaine before retesting. All behaviors were automatically scored using AnyMaze video tracking software (Stoelting) to avoid the introduction of bias and analyzed using Prism 6 (GraphPad).
RIA.
Binding curves and competitive RIA were carried out on 5 kDa MWCO Equilibrium Dialyzer-96 plates (Harvard Apparatus, Holliston, MA) as described previously. 3 Briefly, pooled mouse serum was diluted in 2% BSA to a concentration that bound ∼50% of levo-[benzoyl-3,4-3 H(N)]-cocaine tracer (PerkinElmer). Sample chambers were loaded with 75 μL of diluted serum and 75 μL of radiolabeled cocaine, and buffer chambers were loaded with 150 μL of unlabeled cocaine at indicated concentrations in 1% BSA. Dialysis plates were equilibrated at ambient temperature for 22 h, after which a 75 μL aliquot was removed from each side and diluted into 5 mL of scintillation fluid (Ecolite(+), MP Biomedicals, Santa Ana, CA). Radioactivity (dpm) was measured in a Beckman LS 6500 scintillation counter. Average dissociation constants and antibody concentrations were obtained using Microsoft Excel and GraphPad Prism 6. 
